This phase I/II trial studies the side effects and best dose of SNDX-5613 and and to see how well it works in combination with decitabine/cedazuridine and venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). SNDX-5613 blocks signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving SNDX-5613 with decitabine/cedazuridine and venetoclax may help control acute myeloid leukemia.
Additional locations may be listed on ClinicalTrials.gov for NCT05360160.
Locations matching your search criteria
United States
Texas
Houston
M D Anderson Cancer CenterStatus: Active
Contact: Ghayas C Issa
Phone: 713-745-6798
PRIMARY OBJECTIVES:
I. To determine the safety, tolerability, and recommended phase II dose (RP2D) of SNDX-5613 (or revumenib) in combination with oral decitabine/cedazuridine (ASTX727) and venetoclax for patients with acute myeloid leukemia (AML). (Phase Ib)
II. To assess the efficacy of SNDX-5613 in combination with ASTX727 and venetoclax for patients with newly diagnosed or relapse/refractory AML. (Phase II)
SECONDARY OBJECTIVE:
I. To assess overall survival, relapse-free survival, event-free survival survival and duration of response.
II. To assess minimal residual disease negativity by flow cytometry.
III. To assess the proportion of patients proceeding to a stem cell transplant.
IV. To characterize the pharmacokinetic profile of SNDX-5613 (revumenib) when used in combination with oral decitabine/cedazuridine (ASTX727) and venetoclax.
EXPLORATORY OBJECTIVE:
I. To evaluate molecular and cellular markers that may be predictive of antitumor activity and/or resistance.
OUTLINE: This is a phase I dose-escalation study, followed by a phase II dose expansion study.
Patients receive menin-MLL interaction inhibitor SNDX-5613 orally (PO) every 12 hours on days 1-28, decitabine and cedazuridine PO once daily (QD) in days, 1-5, and venetoclax PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography or multigated acquisition (MUGA) scan during screening and bone marrow biopsy and aspiration and blood sample collection throughout the study.
After completion of study treatment, patients are followed up every 3 months for up to 3 years.
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorGhayas C Issa